Related references
Note: Only part of the references are listed.Model-based drug discovery: implementation and impact
Sandra A. G. Visser et al.
DRUG DISCOVERY TODAY (2013)
The virtue of translational PKPD modeling in drug discovery: selecting the right clinical candidate while sparing animal lives
Tjerk Bueters et al.
DRUG DISCOVERY TODAY (2013)
Pharmacokinetics and the drug-target residence time concept
Goran Dahl et al.
DRUG DISCOVERY TODAY (2013)
Synthesis, Structure-Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials
Thomas H. Marsilje et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic-Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor
Harvey Wong et al.
CLINICAL CANCER RESEARCH (2012)
Mathematical modeling of tumor growth and tumor growth inhibition in oncology drug development
Apexa Bernard et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2012)
Target-Mediated Pharmacokinetic and Pharmacodynamic Model of Exendin-4 in Rats, Monkeys, and Humans
Wei Gao et al.
DRUG METABOLISM AND DISPOSITION (2012)
Pharmacokinetic-Pharmacodynamic Analysis of Vismodegib in Preclinical Models of Mutational and Ligand-Dependent Hedgehog Pathway Activation
Harvey Wong et al.
CLINICAL CANCER RESEARCH (2011)
BRAFV600E: Implications for Carcinogenesis and Molecular Therapy
Emma R. Cantwell-Dorris et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Systems Pharmacology: Bridging Systems Biology and Pharmacokinetics-Pharmacodynamics (PKPD) in Drug Discovery and Development
Piet H. van der Graaf et al.
PHARMACEUTICAL RESEARCH (2011)
Imaging of Plasmodium Liver Stages to Drive Next-Generation Antimalarial Drug Discovery
Stephan Meister et al.
SCIENCE (2011)
Application of In Vivo Animal Models to Characterize the Pharmacokinetic and Pharmacodynamic Properties of Drug Candidates in Discovery Settings
Benny M. Amore et al.
COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING (2010)
Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Inhibition and Biomarker Modulation by the Novel Phosphatidylinositol 3-Kinase Inhibitor GDC-0941
Laurent Salphati et al.
DRUG METABOLISM AND DISPOSITION (2010)
Assessing brain free fraction in early drug discovery
Kevin D. Read et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2010)
Practical evaluation of a mouse with chimeric human liver model for hepatitis C virus infection using an NS3-4A protease inhibitor
Naohiro Kamiya et al.
JOURNAL OF GENERAL VIROLOGY (2010)
Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice
Nelson L. Jumbe et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2010)
Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies
Vishal S. Vaidya et al.
NATURE BIOTECHNOLOGY (2010)
The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery
Dennis A. Smith et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Optimising in vivo pharmacology studies-Practical PKPD considerations
Johan Gabrielsson et al.
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS (2010)
Practical Anticipation of Human Efficacious Doses and Pharmacokinetics Using In Vitro and Preclinical In Vivo Data
Tycho Heimbach et al.
AAPS JOURNAL (2009)
Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100
Rosie Z. Yu et al.
BIOCHEMICAL PHARMACOLOGY (2009)
Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations
Johan Gabrielsson et al.
DRUG DISCOVERY TODAY (2009)
Incorporating Receptor Theory in Mechanism-Based Pharmacokinetic-Pharmacodynamic (PK-PD) Modeling
Bart A. Ploeger et al.
DRUG METABOLISM AND PHARMACOKINETICS (2009)
Scaling Pharmacodynamics from In Vitro and Preclinical Animal Studies to Humans
Donald E. Mager et al.
DRUG METABOLISM AND PHARMACOKINETICS (2009)
Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics
Leonid Gibiansky et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2009)
Population Pharmacokinetic Model of the Pregabalin-Sildenafil Interaction in Rats: Application of Simulation to Preclinical PK-PD Study Design
Gregor Bender et al.
PHARMACEUTICAL RESEARCH (2009)
Predicting oral clearance in humans - How close can we get with allometry?
Vikash K. Sinha et al.
CLINICAL PHARMACOKINETICS (2008)
Development of translational pharmacokinetic-pharmacodynamic models
D. E. Mager et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Monoclonal Antibody Pharmacokinetics and Pharmacodynamics
W. Wang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Plasma/Serum Protein Binding Determinations
Michael J. Banker et al.
CURRENT DRUG METABOLISM (2008)
PK/PD modelling and simulations: utility in drug development
Iris Rajman
DRUG DISCOVERY TODAY (2008)
Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available cMet kinase inhibitor in human tumor xenograft mouse models
Shinji Yamazaki et al.
DRUG METABOLISM AND DISPOSITION (2008)
Validation of a rapid equilibrium dialysis approach for the measurement of plasma protein binding
Nigel J. Waters et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2008)
Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models
Shining Wang et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research
Meindert Danhof et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2008)
Tissue concentrations: do we ever learn?
Johan W. Mouton et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics
Balaji M. Agoram et al.
DRUG DISCOVERY TODAY (2007)
Pharmacokinetic-pharmacodynamic modeling of the effect of fluvoxamine on p-chloroamphetamine-induced behavior
Marian Geldof et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2007)
Application of allometric principles for the prediction of pharmacokinetics in human and veterinary drug development
Iftekhar Mahmood
ADVANCED DRUG DELIVERY REVIEWS (2007)
Model-based drug development
R. L. Lalonde et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: Comparison of unbound concentration ratios to in vivo P-glycoprotein efflux ratios
J. Cory Kalvass et al.
DRUG METABOLISM AND DISPOSITION (2007)
Pharmacokinetics-pharmacodynamics of antimicrobial therapy: It's not just for mice anymore
Paul G. Ambrose et al.
CLINICAL INFECTIOUS DISEASES (2007)
The importance of plasma protein binding in drug discovery
George L. Trainor
EXPERT OPINION ON DRUG DISCOVERY (2007)
Elimination mechanisms of therapeutic monoclonal antibodies
MA Tabrizi et al.
DRUG DISCOVERY TODAY (2006)
Pharmacodynamic assessment of the benztropine analogues AHN-1055 and AHN-2005 using intracerebral microdialysis to evaluate brain dopamine levels and pharmacokinetic/pharmacodynamic modeling
S Raje et al.
PHARMACEUTICAL RESEARCH (2005)
How modeling and simulation have enhanced decision making in new drug development
R Miller et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2005)
Pharmacokinetics/pharmacodynamics and the stages of drug development: Role of modeling and simulation
JY Chien et al.
AAPS JOURNAL (2005)
Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents
M Simeoni et al.
CANCER RESEARCH (2004)
Prediction of human pharmacokinetic profile in animal scale up based on normalizing time course profiles
T Wajima et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2004)
CYP3A induction by liver X receptor ligands in primary cultured rat and mouse hepatocytes is mediated by the pregnane X receptor
SD Shenoy et al.
DRUG METABOLISM AND DISPOSITION (2004)
Antibody pharmacokinetics and pharmacodynamics
ED Lobo et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2004)
Pharmacodynamics of morphine-induced neuronal nitric oxide production and antinociceptive tolerance development
EL Heinzen et al.
BRAIN RESEARCH (2004)
Diversity of mechanism-based pharmacodynamic models
DE Mager et al.
DRUG METABOLISM AND DISPOSITION (2003)
Biomarkers in drug discovery and development: From target identification through drug marketing
WA Colburn
JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Animal model pharmacokinetics and pharmacodynamics: a critical review
D Andes et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2002)
Modeling and simulation for clinical trial design involving a categorical response: A phase II case study with naratriptan
I Nestorov et al.
PHARMACEUTICAL RESEARCH (2001)
Share Paper
